Impact of surgical approach (open vs. minimally invasive) on oncological outcomes after nephrectomy for localised renal cell carcinoma: a recur database project
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426
Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC)
Predicting intra‐operative and postoperative consequential events using machine‐learning techniques in patients undergoing robot‐assisted partial nephrectomy: a Vattikuti Collective Quality Initiative database study